Moderna (CHIX:0QFD) General and Admin. Expense: €0 Mil (TTM As of Mar. 2026)


CHIX:0QFD Moderna Inc CHIX:0QFD
58 GF Score
Price €42.71
GF Value €14.56
! 7 Warning Signs
View Full Analysis

What is Moderna General and Admin. Expense?

Moderna CHIX:0QFD 58 General and Admin. Expense is €0 Mil as of Mar. 2026. GuruFocus rates CHIX:0QFD with a GF Score™ of 58/100 and a GF Value™ of €14.56. The stock has 7 warning signs investors should review.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. Moderna's General and Admin. Expense for the three months ended in Mar. 2026 was €0 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €0 Mil.

Moderna General and Admin. Expense Related Terms

Moderna General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for Moderna's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Moderna General and Admin. Expense Chart

Moderna Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
General and Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Moderna Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CHIX:0QFD
58GF Score
Moderna Inc CHIX:0QFD
General and Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Moderna General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a General and Admin. Expense of €0 Mil mean?
Moderna (CHIX:0QFD) has a General and Admin. Expense of €0 Mil as of Mar. 2026. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Moderna and its competitors.
Is Moderna's General and Admin. Expense too high?
Moderna's current General and Admin. Expense is €0 Mil. Overall, Moderna has a GF Score™ of 58/100, reflecting its overall financial health beyond just this single metric.
How does Moderna's General and Admin. Expense compare to RPRX and ROIV?
Moderna's General and Admin. Expense of €0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Biotechnology company?
A good General and Admin. Expense depends on the Biotechnology industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Moderna and its competitors. Moderna's current General and Admin. Expense is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moderna stock overvalued right now?
Moderna (CHIX:0QFD) has a current General and Admin. Expense of €0 Mil. The stock's GF Value™ is €14.56, compared to a current price of €42.71 — trading 193.3% above its estimated fair value. The current General and Admin. Expense is €0 Mil. Moderna's overall GF Score™ is 58/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For Moderna (CHIX:0QFD), the current General and Admin. Expense is €0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Moderna (CHIX:0QFD) Overvalued in 2026?

Based on GuruFocus' analysis, Moderna stock appears to be overvalued. The current stock price of €42.71 is trading 193.3% above its estimated GF Value™ of €14.56.

Key valuation signals for CHIX:0QFD:

  • General and Admin. Expense: €0 Mil
  • GF Value™: €14.56 vs. price of €42.71 (193.3% above fair value)
  • GF Score™: 58/100 with 7 warning signs

No single metric tells the full story. See the CHIX:0QFD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Moderna Business Description

Address 325 Binney Street, Cambridge, MA, USA, 02142
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
58GF Score

Get the complete analysis for CHIX:0QFD

General and Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€42.71
Price
€14.56
GF Value